See related research article by Tonelli and colleagues at www. cmaj. ca/lookup/doi/10.1503/
cmaj. 101280 and synopsis on page 1845, and related research article by Conly and …

The assessment by Douglas Manuel and associates1 of the 2003 Canadian dyslipidemia
guidelines2 is welcome, but they overlooked the all-cause mortality issue, where statins …

This discussion was sparked by an editorial critique by Sniderman et al 1 regarding the
2010 Cholesterol Treatment Trialists'(CTT) meta-analysis that suggested a statin …

Statins are first‐line evidence‐based drugs for the management of dyslipidaemias and to
reduce the risk of cardiovascular events. However, statin clinical trials have shown …

In considering whether a patient should be placed on a preventive medication, the focus
should be on outcomes that balance risks and benefits to the patientrather than outcomes …

Despite remarkable declines in mortality, cardiovascular disease (CVD) will remain the
major cause of premature death in the United States and is becoming the major cause of …

Vos et al title their article '''Why statins have failed to reduce mortality in just about
anybody.''1 The simple, straightforward, uncomplicated, and direct answer to their question …

The Statin Safety Assessment Conference of the National Lipid Association (NLA), reported
in this supplement to The American Journal of Cardiology, provides a comprehensive …

Statins are back in the news. A review published in the Lancet last week, covered in our
news story (doi: 10.1136/bmj. i4893), presents what its authors clearly consider to be a …

It is old news that older adults constitute an understudied population in clinical trials. Primary
prevention statin trials are no exception because most have included few patients age> 70 …